Dr. Reddy's Laboratories Ltd. has launched Sevelamer Carbonate tablets, 800 mg, a therapeutic equivalent generic version of Renvela (Sevelamer Carbonate) tablets, approved by the US FDA. This is the company's eighth overall and fourth limited-competition launch this fiscal year.

The Renvela brand and generic had US sales of approximately 12,595 crore (USD 1.88 billion) moving annual total (MAT) for the most recent twelve months ending in July 2017 according to IMS Health. Dr. Reddy's Sevelamer Carbonate tablets, 800 mg are available in the bottle count size of 270 tablets. Renvela is a trademark of Genzyme Corporation.


10 Diagnostic Imaging Trends for 2018

Best of 2017 Medical

 

Digital version